A09722 Summary:

BILL NOA09722
 
SAME ASSAME AS S08618
 
SPONSORReyes
 
COSPNSRLupardo, Abinanti
 
MLTSPNSR
 
Amd §3307, Pub Health L
 
Requires the commissioner of health by regulation or emergency regulation, to reclassify any compound, mixture or preparation containing any substance listed in Schedule I of section three thousand three hundred six of the public health law as a Schedule II, III, IV or V substance, or exempt it, if that same compound, mixture or preparation is redesignated or rescheduled other than under Schedule I under the federal Controlled Substances Act, or deleted as a controlled substance under the federal Controlled Substances Act.
Go to top    

A09722 Actions:

BILL NOA09722
 
03/28/2022referred to health
05/03/2022reported referred to codes
05/10/2022reported referred to rules
05/16/2022reported
05/16/2022rules report cal.239
05/16/2022substituted by s8618
 S08618 AMEND= RIVERA
 03/22/2022REFERRED TO HEALTH
 04/26/20221ST REPORT CAL.893
 04/27/20222ND REPORT CAL.
 05/02/2022ADVANCED TO THIRD READING
 05/03/2022PASSED SENATE
 05/03/2022DELIVERED TO ASSEMBLY
 05/03/2022referred to codes
 05/16/2022substituted for a9722
 05/16/2022ordered to third reading rules cal.239
 05/16/2022passed assembly
 05/16/2022returned to senate
 12/12/2022DELIVERED TO GOVERNOR
 12/23/2022SIGNED CHAP.777
Go to top

A09722 Committee Votes:

CODES Chair:Dinowitz DATE:05/10/2022AYE/NAY:21/0 Action: Favorable refer to committee Rules
DinowitzAyeMorinelloAye
PretlowAyeGiglioAye
CookAyeMontesanoAye
CymbrowitzAyeReillyAye
O'DonnellAyeMikulinAye
LavineAyeTannousisAye
AbinantiAye
WeprinAye
HevesiAye
SeawrightAye
RosenthalAye
WalkerAye
VanelAye
CruzAye
CarrollAye

RULES Chair:Gottfried DATE:05/16/2022AYE/NAY:26/0 Action: Favorable
HeastieExcusedBarclayAye
GottfriedAyeHawleyAye
NolanAyeGiglioAye
WeinsteinExcusedBlankenbushAye
PretlowAyeNorrisAye
CookAyeMontesanoAye
GlickAyeRaAye
AubryAyeBrabenecAye
EnglebrightAye
DinowitzAye
ColtonAye
MagnarelliAye
PaulinAye
Peoples-StokesExcused
BenedettoExcused
LavineAye
LupardoAye
ZebrowskiAye
ThieleAye
BraunsteinAye
DickensExcused
DavilaAye
HyndmanAye

HEALTH Chair:Gottfried DATE:05/03/2022AYE/NAY:25/0 Action: Favorable refer to committee Codes
GottfriedAyeByrneAye
GalefAyeMcDonoughAye
DinowitzExcusedByrnesAye
CahillAyeAshbyAye
PaulinAyeSalkaAye
CymbrowitzAyeJensenAye
GuntherAyeGandolfoAye
Rosenthal L Aye
HevesiAye
SteckAye
AbinantiAye
BraunsteinAye
SolagesAye
BichotteAye
SayeghAye
Rosenthal D Aye
McDonaldAye
ReyesAye
Gonzalez-RojasAye

Go to top

A09722 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
 
BILL NUMBER: A9722
 
SPONSOR: Reyes
  TITLE OF BILL: An act to amend the public health law, in relation to providing for the automatic rescheduling of certain compounds, mixtures or preparations   PURPOSE: To provide for parity between the New York State schedule and the feder- al schedule when certain drugs are approved for medical treatment   SUMMARY OF PROVISIONS: Section 1 amends subdivision 5 of section 3307 of the public health law to provide that the commissioner of the Department of Health shall, by regulation or emergency regulation, reclassify a compound, mixture, or preparation containing a substance which is listed as a Schedule I, Schedule II, Schedule III, Schedule IV, or Schedule V substance or exempt it, if rescheduled per federal regulation. Section 2 provides for the effective date, which is immediately.   JUSTIFICATION: As of 2022, twenty-three states have granted the authority to schedule or reschedule controlled substances to be in par with a federal schedul- ing decision effectuated by regulation. This formulary ensures that even if the U.S. Food and Drug Administration (FDA) classifies or reclassi- fies a drug product for prescription use while the state legislature is not in session, these drug products will be available for administration by medical providers to ensure that there are no gaps in services. This legislation would require the Commissioner of Health to schedule or reschedule an FDA-approved drug product using regulatory action upon federal scheduling or rescheduling by the Drug Enforcement Adminis- tration (DEA). Without the statutory authority to automatically classify or reclassify certain drug products, New Yorkers might experience a delay in accessing and benefitting from federally approved breakthrough therapies, such as MDMA-assisted therapies for post-traumatic stress disorder or psilocybin treatment for depression.   LEGISLATIVE HISTORY: New bill.   FISCAL IMPLICATIONS: Undetermined.   EFFECTIVE DATE: This act shall take effect immediately.
Go to top